← Therapy pipeline
Investigational · Obesity development

Olatorepatide

HS-20094 · Hansoh / Regeneron

Dual-biased GLP-1/GIP agonist with Phase 3 LIGHTEN primary results presented at EASD 2026; global development and regulatory outcomes remain ahead.

GLP-1GIP
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorHansoh / Regeneron
TargetsGLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

LIGHTEN Phase 3 primary results · EASD 2026Mean body-weight change from baseline at week 48Body weight decreased 19.3% · 48 weeks · Phase 3
Phase 3 · Injection · Sponsor-reported conference results; peer-reviewed publication not located

Mean body-weight change from baseline at week 48 · 48 weeks

Study focus: Weight management

Olatorepatide 15 mg · efficacy estimand
19.3%
Placebo / comparator
2.7%

Chinese adults with overweight or obesity · 15 mg once weekly vs placebo · Trial N=604 · Efficacy estimand; sponsor-reported EASD 2026 LBA 27 results. Results & methods ↗

Additional results or analyses from this same study
  • Other doses · efficacy estimandAt week 48, mean body-weight change was −12.5% with 5 mg, −17.5% with 10 mg, and −19.3% with 15 mg, versus −2.7% with placebo. Follow-up source ↗
  • Treatment-regimen estimandAt week 48, mean body-weight change was −11.8% with 5 mg, −17.0% with 10 mg, and −18.7% with 15 mg, versus −2.5% with placebo. Follow-up source ↗
  • Study completion90.1% of participants completed the 48-week treatment period. Follow-up source ↗

Conference abstract results reported in a sponsor-issued release; peer-reviewed full publication not located. Study enrolled adults in China.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3China trial completed; global Phase 3 planned
Milestone → next

Latest: LIGHTEN Phase 3 primary results presented as EASD 2026 Late-Breaking Abstract 27.

Next: Peer-reviewed LIGHTEN results and global RISE-1 initiation; RISE-1 is registered, not yet recruiting.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 3

LIGHTEN (HS-20094-301)

Weight management
Study: CompletedResults: Full primary results presented at EASD 2026 (LBA 27); sponsor-reported conference release; peer-reviewed publication not located.Status reviewed November 2026

Randomized, double-blind, placebo-controlled Phase 3 study in 604 Chinese adults with overweight or obesity; once-weekly 5, 10, or 15 mg or placebo for 48 weeks.

Phase 3

RISE-1 · global

Weight management
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Registered global Phase 3, estimated 3,000 participants and a week-72 weight endpoint; not yet recruiting, with an estimated November 18, 2026 start. Distinct from China LIGHTEN.